SavedAdd your journal

Journals / Acıbadem Üniversitesi Sağlık Bilimleri Dergisi / 2022 / Cilt: 13 - Sayı: 3

The Efficacy of Low-Dose Enoxaparin in Psoriasis

Deniz DEMİRCİOĞLU
Nilgün ATAKAN
Pages
352–359
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Four out of 23 patients (17%) showed marked improvement (≥50% reduction in the PASI score), eight patients (35%) showed moderate improvement (25-49% reduction), five (22%) were unchanged (

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Psoriasis is a frequently encountered inflammatory skin disease with unclear etiology and no curative therapy.
📊
Key Findings & Data:Patients were given subcutaneous injections of 5 mg enoxaparin once weekly for a total of 6 weeks.
💡
Conclusion & Impact:Four out of 23 patients (17%) showed marked improvement (≥50% reduction in the PASI score), eight patients (35%) showed moderate improvement (25-49% reduction), five (22%) were unchanged (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Psoriasis is a frequently encountered inflammatory skin disease with unclear etiology and no curative therapy. Enoxaparin is a low-molecular weight heparin analogue. Heparin and its analogues in low doses have antiproliferative and immunomodulatory effects. Low-dose enoxaparin has inhibitory effects on T cell-mediated immune reactions. T lymphocytes play a key role in the immunpathogenesis of psoriasis. The aim of this study was to evaluate the efficacy of low-dose enoxaparin in the treatment of psoriasis. Twenty-three patients with chronic plaque and guttate psoriasis were enrolled in an open study. Patients were given subcutaneous injections of 5 mg enoxaparin once weekly for a total of 6 weeks. There was a statistically significant difference between the PASI (Psoriasis Area and Severity Index) scores at the beginning and at the 6th week follow up (p=0.008). Four out of 23 patients (17%) showed marked improvement (≥50% reduction in the PASI score), eight patients (35%) showed moderate improvement (25-49% reduction), five (22%) were unchanged (

🔖

Cite This Article

DEMİRCİOĞLU, D., ATAKAN, N. (2022). The Efficacy of Low-Dose Enoxaparin in Psoriasis. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 13 - Sayı: 3, 352–359. https://ajindex.com/articles/427379

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-10
  2. Prinz JC. Psoriasis vulgaris - a sterile antibacterial reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26: 326-32
  3. Mrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001; 26: 362-7
  4. Lider O, Baharav E, Mekori YA, et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989; 83: 752-6
  5. Lider O, Mekori YA, Miller T, et al. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990; 20: 493-9
  6. Cahalon L, Lider O, Schor H, et al. Heparin disaccharides inhibit tumor necrosis factor-alpha production by macrophages and arrest immune inflammation in rodents. Int Immunol 1997; 9: 1517-22
  7. Pillai S, Gilliam L, Conrad HE, et al. Heparin and its non-anticoagulant analogues inhibit human keratinocyte growth without inducing differentiation. J Invest Dermatol 1994; 103: 647-50
  8. Hodak E, Yosipovitch G, David M, et al. Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report. J Am Acad Dermatol 1998; 38: 564-8
  9. Stefanidou MP, Ioannidou DJ, Panayiotides JG, et al. Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus. Br J Dermatol 1999; 141: 1040-5
  10. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44
  11. Prinz JC, Gross B, Vollmer S, et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 1994; 24: 593-8
  12. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, et al. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 1995; 95: 317-27
  13. Naparstek Y, Cohen IR, Fuks Z, et al. Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 1984; 310: 241-4
  14. Fridman R, Lider O, Naparstek Y, et al. Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extrac